These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17256680)

  • 1. Comparative safety and efficacy of subcutaneous and intradermal administration of inactivated Japanese encephalitis vaccine during predeployment preparations in the Australian Defence Force.
    Kitchener S; Nasveld P; Brennan L; Ward D
    Mil Med; 2006 Dec; 171(12):1190-5. PubMed ID: 17256680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis.
    Erra EO; Kantele A
    Expert Rev Vaccines; 2015; 14(9):1167-79. PubMed ID: 26162529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.
    Tauber E; Kollaritsch H; Korinek M; Rendi-Wagner P; Jilma B; Firbas C; Schranz S; Jong E; Klingler A; Dewasthaly S; Klade CS
    Lancet; 2007 Dec; 370(9602):1847-53. PubMed ID: 18061060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.
    Cramer JP; Jelinek T; Paulke-Korinek M; Reisinger EC; Dieckmann S; Alberer M; Bühler S; Bosse D; Meyer S; Fragapane E; Costantini M; Pellegrini M; Lattanzi M; Dovali C
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 26994987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal boosting of Japanese encephalitis vaccination.
    Kitchener S; Baade L; Brennan L; Nasveld P
    J Travel Med; 2004; 11(3):182-3. PubMed ID: 15710061
    [No Abstract]   [Full Text] [Related]  

  • 10. Product review on the JE vaccine IXIARO.
    Firbas C; Jilma B
    Hum Vaccin Immunother; 2015; 11(2):411-20. PubMed ID: 25621812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
    Rabe IB; Miller ER; Fischer M; Hills SL
    Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Sabchareon A; Pancharoen C; Bouckenooghe A; Gailhardou S; Boaz M; Feroldi E
    Pediatr Infect Dis J; 2010 Dec; 29(12):1111-7. PubMed ID: 20856164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK(®)V) in children.
    Okada K; Iwasa T; Namazue J; Akechi M; Ueda S;
    Vaccine; 2012 Sep; 30(41):5967-72. PubMed ID: 22841478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
    Kaltenböck A; Dubischar-Kastner K; Eder G; Jilg W; Klade C; Kollaritsch H; Paulke-Korinek M; von Sonnenburg F; Spruth M; Tauber E; Wiedermann U; Schuller E
    Vaccine; 2009 Jul; 27(33):4483-9. PubMed ID: 19486955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of low dose Japanese encephalitis vaccine (BIKEN) administered by the intradermal route: preliminary data.
    Intralawan P; Paupunwatana S
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):79-83. PubMed ID: 8216563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.
    Yang SE; Pan MJ; Tseng HF; Liau MY
    Vaccine; 2006 Mar; 24(14):2669-73. PubMed ID: 16314007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese encephalitis: update on vaccines and vaccine recommendations.
    Wilder-Smith A; Halstead SB
    Curr Opin Infect Dis; 2010 Oct; 23(5):426-31. PubMed ID: 20581670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.